Edgar Filing: IDEXX LABORATORIES INC /DE

Ownership Submission

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0287

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

RAINES MERILEE

2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [IDXX]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director	_____ 10% Owner
__X__ Officer (give title below)	_____ Other (specify below)
Executive VP & CFO

(Last)

(First)

(Middle)

ONE IDEXX DRIVE

3. Date of Earliest Transaction (Month/Day/Year)
02/01/2013

(Street)

WESTBROOK, ME 04092

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/01/2013		M		13,581	A	$ 34.37	51,581	D
Common Stock	02/01/2013		S		13,581	D	$ 94.4108 ⁽¹⁾	38,000	D
Common Stock	02/01/2013		S		31,900	D	$ 94.7466 ⁽²⁾	6,100	D
Common Stock	02/01/2013		S		6,100	D	$ 95.864 ⁽³⁾	0	D
Common Stock	02/01/2013		S		29,052	D	$ 94.7439 ⁽⁴⁾	5,948	I	by Charitable Remainder Trust
Common Stock	02/01/2013		S		5,948	D	$ 95.8086 ⁽⁵⁾	0	I	by Charitable Remainder Trust
Common Stock	02/04/2013		M		20,440	A	$ 41.935	20,440	D
Common Stock	02/04/2013		M		26,000	A	$ 28.655	46,440	D
Common Stock	02/04/2013		M		24,000	A	$ 25.45	70,440	D
Common Stock	02/04/2013		M		17,736	A	$ 56.95	88,176	D
Common Stock	02/04/2013		M		1	A	$ 34.37	88,177	D
Common Stock	02/04/2013		M		8,120	A	$ 53.31	96,297	D
Common Stock	02/04/2013		M		2,851	A	$ 77.59	99,148	D
Common Stock	02/04/2013		S		84,486	D	$ 93.6295 ⁽⁶⁾	14,662	D
Common Stock	02/04/2013		S		4,862	D	$ 94.3454 ⁽⁷⁾	9,800	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code
(Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date
(Month/Day/Year)

7. Title and Amount of Underlying Securities
(Instr. 3 and 4)

8. Price of Derivative Security
(Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)

11. Nature of Indirect Beneficial Ownership
(Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Non-Qualified Stock Option (right to buy)

$ 34.37

02/01/2013

13,581

⁽⁸⁾

02/13/2016

Common Stock

13,581

$ 0

6,144

Incentive Stock Option (right to buy)

$ 41.935

02/04/2013

2,384

⁽⁹⁾

02/13/2014

Common Stock

2,384

$ 0

Incentive Stock Option (right to buy)

$ 28.655

02/04/2013

3,488

⁽¹⁰⁾

02/02/2015

Common Stock

3,488

$ 0

Incentive Stock Option (right to buy)

$ 25.45

02/04/2013

3,928

⁽¹¹⁾

02/04/2014

Common Stock

3,928

$ 0

Non-Qualified Stock Option (right to buy)

$ 28.655

02/04/2013

22,512

⁽¹²⁾

02/02/2015

Common Stock

22,512

$ 0

Non-Qualified Stock Option (right to buy)

$ 41.935

02/04/2013

18,056

⁽¹³⁾

02/13/2014

Commom Stock

18,056

$ 0

Non-Qualified Stock Option (right to buy)

$ 56.95

02/04/2013

17,736

⁽¹⁴⁾

02/13/2015

Common Stock

17,736

$ 0

2,678

Incentive Stock Option (right to buy)

$ 34.37

02/04/2013

⁽¹⁵⁾

02/13/2016

Common Stock

$ 0

2,910

Non-Qualified Stock Option (right to buy)

$ 53.31

02/04/2013

8,120

⁽¹⁶⁾

02/13/2017

Common Stock

8,120

$ 0

10,303

Non-Qualified Stock Option (right to buy)

$ 77.59

02/04/2013

2,851

⁽¹⁷⁾

02/13/2018

Common Stock

2,851

$ 0

10,116

Non-Qualified Stock Option (right to buy)

$ 25.45

02/04/2013

20,072

⁽¹⁸⁾

02/04/2014

Common Stock

20,072

$ 0

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
RAINES MERILEE ONE IDEXX DRIVE WESTBROOK, ME 04092			Executive VP & CFO

Signatures

Conan R. Deady, Attorney-in-Fact for Merilee Raines		02/05/2013
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $94.24 to $94.64, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1, 2, 3, 4, 5, 6 and 7 to this Form 4.
(2)	The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $94.22 to $95.21, inclusive.
(3)	The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $95.22 to $96.18, inclusive.
(4)	The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $94.24 to $95.23, inclusive.
(5)	The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $95.24 to $96.19, inclusive.
(6)	The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $93.26 to $94.20, inclusive.
(7)	The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $94.28 to $94.46, inclusive.
(8)	Grant of options to buy shares of common stock becomes exercisable as to 4,527 shares on 02/14/2010, 02/14/2011 and 02/14/2012, 4,526 shares on 02/14/2013, and the remaining 1,618 shares on 02/14/2014.
(9)	Grant of options to buy shares of common stock that vest on the fifth anniversary date (02/14/2012) of the grant.
(10)	Grant of options to buy shares of common stock that vest on the fifth anniversary date (02/03/2010) of the grant.
(11)	Grant of options to buy shares of common stock that vest on the fifth anniversary date (02/05/2009) of the grant.
(12)	Grant of options to buy shares of common stock becomes exercisable as to 5,200 shares on 02/03/2006, 02/03/2007, 02/03/2008, and 02/03/2009, and the remaining 1,712 shares on 02/03/2010.
(13)	Grant of options to buy shares of common stock becomes exercisable as to 4,088 shares on 02/14/2008, 02/14/2009, 02/14/2010, and 02/14/2011, and the remaining 1,704 shares on 02/14/2012.
(14)	Grant of options to buy shares of common stock becomes exercisable as to 4,434 shares on 02/14/2009, 02/14/2010, 02/14/2011, and 02/14/2012, and the remaining 2,678 shares on 02/14/2013.
(15)	Grant of options to buy shares of common stock becomes exercisable as to 1 share on 02/14/2010 and 02/14/2013, and the remaining 2,909 shares on 02/14/2014.
(16)	Grant of options to buy shares of common stock becomes exercisable as to 4,060 shares on 02/14/2011, 02/14/2012 and 02/14/2013, 4,059 shares on 02/14/2014, and the remaining 2,184 shares on 02/14/2015.
(17)	Grant of options to buy shares of common stock becomes exercisable as to 2,851 shares on 02/14/2012, 02/14/2013, 02/14/2014 and 02/14/2015, and the remaining 1,563 shares on 02/14/2016.
(18)	Grant of options to buy shares of common stock becomes exercisable as to 4,800 shares on 02/05/2005, 02/05/2006, 02/05/2007 and 02/05/2008, and the remaining 872 shares on 02/05/2009.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.